Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
Alumis reported positive long-term data from the Phase 3 ONWARD3 study, showing that 54% of patients treated with envudeucitinib achieved complete skin clearance (PASI 100) at 48 weeks, the highest reported rate for an oral therapy. The data demonstrated durable responses, with approximately 90% of PASI 90 responders and 80% of PASI 100 responders maintaining clearance through the extension study, alongside a consistent safety profile.
Key figures
- Drug Name
- envudeucitinib
- Guidance
- Submit New Drug Application to FDA in 4Q 2026; LUMUS Phase 2b topline data expected in Q3 2026
- Phase Of Trial
- Phase 3
- Pasi 90 lte
- 75%
- Pasi 100 lte
- 54%
- Rollover rate
- >85%
- Onward3 patients
- 1509
- Pasi 90 sustained
- 90%
- Pasi 100 sustained
- 80%
- Pasi 90 integrated
- 66%
- Pasi 100 integrated
- 47%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.